Event Date/Time: May 11, 2009 End Date/Time: May 12, 2009
Report as Spam


 Vaccine development, supported by infusions of public and private venture capital, is re-entering a golden age as one of the fastest growing sectors in the life-sciences industry. The global vaccines market, worth $25bn in 2009, is expected to sustain double-digit growth over the next 15 years, rising to over $100bn by 2024.

Over the past two centuries, immunisation programs have led to the elimination and/or control of several different infectious diseases including smallpox, polio, measles, mumps and rubella. More recently, the past 30 years have seen significant changes both in the number of businesses involved in vaccine manufacture and the production systems used. These include fewer companies, higher costs, and a shift from egg-based to cell-based processes, to reduce allergenicity, optimise quality and increase output.

While more vaccines are now available than ever before, they have long presented special issues for producers, particularly regarding scale-up, affordability, and change of pace. Enduring challenges include ensuring good laboratory and manufacturing process, maintenance of product stability, and preparing a 100% safe and effective product. With time-to-market and flexibility increasingly important to improve cost-effectiveness, producers are becoming increasingly cognisant of the latest technologies to simplify development and manufacturing.

While the market remains dominated by a select group of key players, technology transfer is increasing between small biotech companies and big pharma. More significantly, with emerging markets set to dominate vaccine manufacturing by 2023, globalisation is being taken seriously as the quickest way to develop a product and increase market access.

By attending this conference you will learn more about current and future trends in vaccine manufacture, namely:
• The switch to cell-based manufacturing of influenza vaccines
• Movement of production away from U.S. and Europe to Brazil, India and China, and the contract manufacturing of vaccines
• Methods to speed up regulatory approval of new vaccine plants or new manufacturing processes and how to minimize delays
• New vaccine technology, e.g. DNA vaccines. Are they easier to manufacture?
• Planning for rapid manufacture of pandemic vaccines (‘bird-flu’, bio-emergency)
• Development in process control, quality control and packaging in vaccines

Who will be there?
Presidents, Chief Executive Officers, Senior VPs, VPs, Global Heads, Chief Scientific Officers, Directors, Franchise Heads, Therapeutic Area Head, Professors, Senior Lecturers, Team Leaders, in:
• Vaccine Equipment and Manufacturing
• Vaccine Application Development
• Biotechnology
• Molecular Biology
• Bioinformatics
• Proteomics, Recombinant Protein/DNA Biotechnology
• Infectious Disease R&D
• Pharmacovigilance and Safety Testing
• Regulatory Affairs
• Strategic Product Development
• External Research
• Manufacturing/Production
• Chemistry Manufacturing and Controls (CMC)
• Procurement & Purchasing
• Cold Chain Supply and Lyophilisation
• Strategic Alliances
• Clinical Product Resourcing
• Supply Outsourcing Project Management
• Contract Management
• Process Development
• Business Development
• Drug Discovery & delivery
• Investment and Venture Capital


BSG Conference Centre, London, UK
United Kingdom